Oct 23 (Reuters) - Sumitovant Biopharma Ltd, along with parent Sumitomo Pharma Co Ltd, has entered into a deal to purchase all shares of Myovant Sciences not already owned by Sumitovant for $27 per share, the companies said in a statement on Sunday. (Reporting by Ann Maria Shibu in Bengaluru; Editing by Shailesh Kuber)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
339 JPY | -2.59% | +2.11% | -27.25% |
May. 14 | Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024 | |
May. 14 | Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.25% | 899M | |
+48.79% | 780B | |
+41.76% | 627B | |
+19.43% | 334B | |
+7.18% | 296B | |
+17.60% | 244B | |
-0.41% | 217B | |
+11.54% | 214B | |
+4.53% | 161B | |
-3.92% | 159B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitovant Biopharma to buy Myovant for $27 per share